Haemers Timothy, Wiesner Jochen, Giessmann Dirk, Verbrugghen Thomas, Hillaert Ulrik, Ortmann Regina, Jomaa Hassan, Link Andreas, Schlitzer Martin, Van Calenbergh Serge
Laboratory for Medicinal Chemistry (FFW), Ghent University, Harelbekestraat 72, 9000 Gent, Belgium.
Bioorg Med Chem. 2008 Mar 15;16(6):3361-71. doi: 10.1016/j.bmc.2007.12.001. Epub 2007 Dec 8.
To expand the structure-activity relationships of fosmidomycin and FR900098, two potent antimalarials interfering with the MEP-pathway, we decided to replace a methylene group in beta-position of the phosphonate moiety of these leads by an oxygen atom. beta-oxa-FR900098 (11) proved equally active as the parent compound. When applied to 4-[hydroxyl(methyl)amino]-4-oxobutyl phosphonic acid, featuring a hydroxamate instead of the retrohydroxamate moiety, a beta-oxa modification yielded a derivative (13) with superior activity against the Plasmodium falciparum 3D7 strain than fosmidomycin, while a gamma-oxa modification resulted in less active derivatives. A bis(pivaloyloxymethyl)ester of phosphonate 13 proved twice as active in inhibiting cultured parasites as a similar prodrug of FR900098.
为了拓展磷霉素和FR900098(两种干扰MEP途径的强效抗疟药)的构效关系,我们决定将这些先导化合物膦酸酯部分β位的亚甲基用一个氧原子取代。β-氧杂-FR900098(11)被证明与母体化合物具有同等活性。当应用于具有异羟肟酸而非逆异羟肟酸部分的4-[羟基(甲基)氨基]-4-氧代丁基膦酸时,β-氧杂修饰产生了一种对恶性疟原虫3D7株活性优于磷霉素的衍生物(13),而γ-氧杂修饰则产生了活性较低的衍生物。膦酸酯13的双(新戊酰氧基甲基)酯在抑制培养的寄生虫方面的活性是FR900098类似前药的两倍。